AstraZeneca to build new Virginia plant as it re-hashes other U.S. investment plans
AstraZeneca to build new Virginia plant as it re-hashes other U.S. investment plans
AstraZeneca will invest US$50bn in the US to expand manufacturing and research
AstraZeneca shares show signs of life after successful trials of hypertension drug
FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca - CNBC
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year. https://t.co/b5hOwTxWaU https://t.co/Wq5EsZGLK5
AstraZeneca to buy EsoBiotec in $1 billion deal to advance cell therapy ambition
221.9BUSD
Type
Common Stock
Exchange
PINK
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
GB0009895292
CUSIP
-
Sector
Healthcare
Industry
Drug Manufacturers - General
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
28.55
PEG Ratio
0.95
Book Value
26.48
Dividend Share
3.1
Dividend Yield
2.22%
Earnings Share
4.97
Wall Street Target Price
-
EPS Estimate Current Year
-
EPS Estimate Next Year
-
EPS Estimate Current Quarter
0
EPS Estimate Next Quarter
0
Most Recent Quarter
-
Revenue TTM
54,982,000,640
Gross Profit TTM
45,328,998,400
EBITDA
18,276,999,168
Profit Margin
14.14%
Return On Assets TTM
8.16%
Return On Equity TTM
19.79%
Revenue Per Share TTM
35.467
Qtly Revenue Growth YOY
7.20%
Diluted Eps TTM
4.97
Qtly Earnings Growth YOY
33.60%
Trailing PE
28.55
Forward PE
15
Price Sales TTM
4.0009
Price Book MRQ
5.3602
Enterprise Value Revenue
4
Enterprise Value EBITDA
15
70.70
2.88%68.65
2.82%40.23
1.11%117.76
0.76%778.17
0.31%168.13
0.14%187.16
0.13%337.00
0.07%114.52
-3.52%317.30
-1.29%